Single Mutations in Cytochrome P450 Oxidoreductase Can Alter the Specificity of Human Cytochrome P450 1A2-Mediated Caffeine Metabolism.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
06 07 2023
Historique:
received: 14 06 2023
revised: 29 06 2023
accepted: 04 07 2023
medline: 31 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

A unique cytochrome P450 (CYP) oxidoreductase (CPR) sustains activities of human microsomal CYPs. Its function requires toggling between a closed conformation enabling electron transfers from NADPH to FAD and then FMN cofactors and open conformations forming complexes and transferring electrons to CYPs. We previously demonstrated that distinct features of the hinge region linking the FAD and FMN domain (FD) modulate conformer poses and their interactions with CYPs. Specific FD residues contribute in a CYP isoform-dependent manner to the recognition and electron transfer mechanisms that are additionally modulated by the structure of CYP-bound substrate. To obtain insights into the underlying mechanisms, we analyzed how hinge region and FD mutations influence CYP1A2-mediated caffeine metabolism. Activities, metabolite profiles, regiospecificity and coupling efficiencies were evaluated in regard to the structural features and molecular dynamics of complexes bearing alternate substrate poses at the CYP active site. Studies reveal that FD variants not only modulate CYP activities but surprisingly the regiospecificity of reactions. Computational approaches evidenced that the considered mutations are generally in close contact with residues at the FD-CYP interface, exhibiting induced fits during complexation and modified dynamics depending on caffeine presence and orientation. It was concluded that dynamic coupling between FD mutations, the complex interface and CYP active site exist consistently with the observed regiospecific alterations.

Identifiants

pubmed: 37509119
pii: biom13071083
doi: 10.3390/biom13071083
pmc: PMC10377444
pii:
doi:

Substances chimiques

Cytochrome P-450 CYP1A2 EC 1.14.14.1
Caffeine 3G6A5W338E
Cytochrome P-450 Enzyme System 9035-51-2
NADPH-Ferrihemoprotein Reductase EC 1.6.2.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Arch Med Sci. 2019 Jul;15(4):1073-1080
pubmed: 31360202
J Biol Chem. 1999 Jan 22;274(4):2045-52
pubmed: 9890963
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Drug Metab Dispos. 2014 Jan;42(1):9-22
pubmed: 24130370
J Biol Chem. 2016 Feb 19;291(8):3990-4003
pubmed: 26719338
J Biol Chem. 2015 Feb 20;290(8):4843-4855
pubmed: 25512382
Arch Biochem Biophys. 2008 Jul 15;475(2):93-9
pubmed: 18455494
Chem Res Toxicol. 2014 Sep 15;27(9):1474-86
pubmed: 25133307
J Biol Chem. 2016 Sep 23;291(39):20487-502
pubmed: 27496950
Chem Commun (Camb). 2019 Nov 18;55(89):13422-13425
pubmed: 31638629
Proteins. 2009;77 Suppl 9:114-22
pubmed: 19768677
Pharmacogenetics. 1992 Apr;2(2):73-7
pubmed: 1302044
Biochem Pharmacol. 2018 Dec;158:134-140
pubmed: 30308189
J Mol Biol. 2012 Jul 20;420(4-5):296-309
pubmed: 22543241
J Biol Chem. 2023 Jun 28;:104977
pubmed: 37390989
Drug Metab Dispos. 2010 Feb;38(2):332-40
pubmed: 19884324
Trends Microbiol. 2020 Jun;28(6):445-454
pubmed: 32396826
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32933097
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Mar 1;65(Pt 3):210-2
pubmed: 19255466
Int J Mol Sci. 2018 Dec 06;19(12):
pubmed: 30563285
J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62
pubmed: 9400033
Biochem Pharmacol. 2008 Aug 15;76(4):543-51
pubmed: 18619574
Biochem Pharmacol. 1994 May 18;47(10):1767-76
pubmed: 8204093
J Xenobiot. 2021 Jun 22;11(3):94-114
pubmed: 34206277
J Biol Chem. 1972 Jun 10;247(11):3601-7
pubmed: 4113125
Chem Res Toxicol. 2019 Jul 15;32(7):1374-1383
pubmed: 31132250
Drug Metab Dispos. 2012 Apr;40(4):754-60
pubmed: 22252407
J Biol Chem. 2007 May 11;282(19):14348-55
pubmed: 17311915
Drug Metab Dispos. 2000 Dec;28(12):1493-504
pubmed: 11095589
Biophys J. 2015 Mar 24;108(6):1527-1536
pubmed: 25809265
Adv Exp Med Biol. 2015;851:247-97
pubmed: 26002739
Pharmacogenet Genomics. 2013 Feb;23(2):41-52
pubmed: 23295917
Pharmacol Ther. 2013 May;138(2):229-54
pubmed: 23353702
Exp Gerontol. 2008 Jul;43(7):638-644
pubmed: 18337037
Biochim Biophys Acta. 1982 Dec 6;709(1):84-90
pubmed: 6817796
Structure. 2013 Sep 3;21(9):1581-9
pubmed: 23911089
Front Pharmacol. 2017 Oct 30;8:755
pubmed: 29163152
Arch Biochem Biophys. 2005 Mar 1;435(1):207-16
pubmed: 15680923
Protein Sci. 2013 Sep;22(9):1183-95
pubmed: 23832577
Pharmacol Rev. 2018 Apr;70(2):384-411
pubmed: 29514871
Chembiochem. 2019 Mar 1;20(5):659-666
pubmed: 30427570
Front Pharmacol. 2022 Feb 25;12:752826
pubmed: 35280254
J Biol Chem. 2011 May 6;286(18):16246-60
pubmed: 21345800
J Biol Chem. 2013 Jun 14;288(24):17082-90
pubmed: 23632020
Pharmacogenet Genomics. 2018 Sep;28(9):214-222
pubmed: 30134346
Pharmacogenomics. 2012 Apr;13(5):543-54
pubmed: 22462747
Commun Biol. 2021 Jan 8;4(1):55
pubmed: 33420418
J Biol Chem. 1995 Nov 17;270(46):27475-80
pubmed: 7499204
Mutagenesis. 2005 Mar;20(2):93-100
pubmed: 15728263
J Biol Chem. 2009 Apr 24;284(17):11374-84
pubmed: 19171935
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8411-6
pubmed: 9237990
J Comput Chem. 2015 May 15;36(13):996-1007
pubmed: 25824339
J Biol Chem. 1992 Jul 25;267(21):14669-76
pubmed: 1321814
J Biol Chem. 2009 Dec 25;284(52):36628-36637
pubmed: 19858215
Front Pharmacol. 2017 Aug 25;8:580
pubmed: 28970799
Anal Chem. 2017 Apr 4;89(7):3853-3857
pubmed: 28224799
Arch Biochem Biophys. 2000 Dec 1;384(1):47-58
pubmed: 11147835
Front Pharmacol. 2020 Mar 18;11:299
pubmed: 32256365
Am J Hum Genet. 2005 May;76(5):729-49
pubmed: 15793702

Auteurs

Francisco Esteves (F)

ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal.

Cristina M M Almeida (CMM)

iMed.UL (Institute for Medicines and Pharmaceutical Sciences, Portugal), Faculty of Pharmacy, University of Lisboa, Av. Prof. Gama Pinto, 2, 1649-003 Lisbon, Portugal.
Laboratory of Bromatology and Water Quality, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 2, 1649-003 Lisbon, Portugal.

Sofia Silva (S)

Laboratory of Bromatology and Water Quality, Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 2, 1649-003 Lisbon, Portugal.

Inês Saldanha (I)

ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal.

Philippe Urban (P)

TBI, Université de Toulouse, CNRS, INRAE, INSA, 135 Avenue de Rangueil, 31077 Toulouse, CEDEX 04, France.

José Rueff (J)

ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal.

Denis Pompon (D)

TBI, Université de Toulouse, CNRS, INRAE, INSA, 135 Avenue de Rangueil, 31077 Toulouse, CEDEX 04, France.

Gilles Truan (G)

TBI, Université de Toulouse, CNRS, INRAE, INSA, 135 Avenue de Rangueil, 31077 Toulouse, CEDEX 04, France.

Michel Kranendonk (M)

ToxOmics, NOVA Medical School, Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH